Praluent Now FDA-Approved for HoFH
At the start of April 2021, the Food and Drug Administration (FDA) approved Regeneron Pharmaceutical's Praluent (alirocumab), a treatment for patients aged 18+ with a rare genetic condition called…
At the start of April 2021, the Food and Drug Administration (FDA) approved Regeneron Pharmaceutical's Praluent (alirocumab), a treatment for patients aged 18+ with a rare genetic condition called…
We’ve all heard the expression, “Beauty is in the eye of the beholder.” How about another cliché? “One man’s trash is another man’s treasure.” These trite statements do, in fact,…